ArticleBritish journal of clinical pharmacology2019

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.

Sander Zuidema et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.